TSOI

Therapeutic Solutions International Inc

TSOI, USA

Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. The company also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. In addition, it develops therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology; and portfolio of immunotherapies that provides dendritic cell vaccines for cancers to Parkinson's disease developed on StemVacs platform. Therapeutic Solutions International, Inc. was founded in 2007 and is headquartered in Elk City, Idaho.

https://www.therapeuticsolutionsint.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TSOI
stock
TSOI

Universal Technologies Shareholders Approve AGM Resolutions as INED Retires The Globe and Mail

Read more →
TSOI
stock
TSOI

Hutchison Port Has Invested USD1.6B in Middle East So Far AASTOCKS.com

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2024-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.39

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-80.03 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.98 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

360.19 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.52

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Therapeutic Solutions International Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-09-30

EPS Actual

-0.0002

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Moderately Defensive(4)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(3.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2024-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.